Covaxin 77.8% Effective Against COVID-19 As Per Lancet Study

Bharat Biotech’s vaccine Covaxin has confirmed that it is 77.8 per cent effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group, Phase III data.

According to the reports, the vaccine demonstrated 63.6 per cent protection against asymptomatic Covid-19 and 65.2 per cent safety against the Delta variant besides showing 70.8 per cent guard against all variants of the SARS-CoV-2 virus. The efficacy analysis demonstrated that Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19.

In an official statement, Bharat Biotech Chairman Krishna Ella stated that the data from our product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin one of the most highly published COVID-19 vaccines in the world. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, the Indian Council of Medical Research, the National Institute of Virology, and the trust imposed by our trial participants who made this happen.

Balram Bhargava, Director General, Indian Council of Medical Research (ICMR) stated that following successful isolation of the SARS-CoV-2 virus at NIV, ICMR and Bharat Biotech embarked upon one of the most successful public-private partnerships to develop the virus isolate into an effective COVID-19 vaccine.

Pic Courtesy – Google